Diplomat Pharmacy (NYSE:DPLO) updated its FY 2019 earnings guidance on Friday. The company provided earnings per share guidance of $-0.5-0.34 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.61. The company issued revenue guidance of $4.7-5 billion, compared to the consensus revenue estimate of $5.45 billion.
Several research firms have recently weighed in on DPLO. Zacks Investment Research cut Diplomat Pharmacy from a hold rating to a strong sell rating in a report on Tuesday, November 27th. William Blair cut Diplomat Pharmacy from an outperform rating to a market perform rating in a report on Monday, January 7th. ValuEngine cut Diplomat Pharmacy from a sell rating to a strong sell rating in a report on Monday, February 4th. Barclays reiterated an overweight rating and set a $8.00 price objective (down previously from $18.00) on shares of Diplomat Pharmacy in a report on Monday, February 25th. Finally, Svb Leerink cut Diplomat Pharmacy from an outperform rating to a market perform rating and cut their price objective for the company from $24.00 to $6.00 in a report on Monday, February 25th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $13.78.
NYSE:DPLO opened at $6.42 on Friday. The stock has a market cap of $485.54 million, a PE ratio of 7.64 and a beta of 0.74. The company has a current ratio of 0.95, a quick ratio of 0.66 and a debt-to-equity ratio of 0.58. Diplomat Pharmacy has a fifty-two week low of $5.56 and a fifty-two week high of $28.74.
COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2019/03/15/diplomat-pharmacy-dplo-updates-fy-2019-earnings-guidance.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
See Also: What is the Coverage Ratio?
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.